Witzens-Harig, M., Memmer, M., Dreyling, M., & Hess, G. (2013). A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial. BMC cancer, 13, . https://doi.org/10.1186/1471-2407-13-308
Chicago Style (17th ed.) CitationWitzens-Harig, Mathias, Marie-Luise Memmer, Martin Dreyling, and Georg Hess. "A Phase I/II Trial to Evaluate the Safety, Feasibility and Activity of Salvage Therapy Consisting of the MTOR Inhibitor Temsirolimus Added to Standard Therapy of Rituximab and DHAP for the Treatment of Patients with Relapsed or Refractory Diffuse Large Cell B-Cell Lymphoma - the STORM Trial." BMC Cancer 13 (2013). https://doi.org/10.1186/1471-2407-13-308.
MLA (9th ed.) CitationWitzens-Harig, Mathias, et al. "A Phase I/II Trial to Evaluate the Safety, Feasibility and Activity of Salvage Therapy Consisting of the MTOR Inhibitor Temsirolimus Added to Standard Therapy of Rituximab and DHAP for the Treatment of Patients with Relapsed or Refractory Diffuse Large Cell B-Cell Lymphoma - the STORM Trial." BMC Cancer, vol. 13, 2013, https://doi.org/10.1186/1471-2407-13-308.